The story of Sildenafil presents a interesting case for stakeholders in the medicinal sector. While initially a tremendous success, producing vast sums, the exclusivity lapse and the subsequent arrival of cheaper competitors have drastically changed revenue. This presents questions about the future profitability of related drug developments and sug